Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 8,509 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Group Clear all
Not yet recruiting Phase 3 Interventional

MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation

NCT07632157
View directory record Official record
Conditions
Atrial Flutter With Rapid Ventricular Response
Interventions
Magnesium Sulfate 2g, Magnesium Sulfate 4g, Saline (0.9% NaCl)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Active, not recruiting No phase listed Observational

Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma

NCT04553757
View directory record Official record
Conditions
Brain Neoplasm, Low Grade Glioma, Seizure Disorder
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional

BBTI vs PSR in Musculoskeletal Orofacial Pain Adults

NCT04897581
View directory record Official record
Conditions
Myofascial Pain, Myalgia
Interventions
Brief Behavioral Therapy for Insomnia, BBTI, Physical Self-Regulation, PSR
Behavioral
Lead sponsor
Ian Boggero, PhD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Recruiting Not applicable Interventional

QL vs LAI for Palatoplasty

NCT06420336
View directory record Official record
Conditions
Post-operative Pain, Opioid Use, Cleft Palate
Interventions
Quadratus lumborum block, Local anesthetic infiltration
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
6 Years to 18 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

NCT00760344
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
SYR-472, Placebo, Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
105
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma

NCT01591044
View directory record Official record
Conditions
Asthma
Interventions
Placebo, R940343 1mg, R940343 2mg
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
51
States / cities
Fullerton, California • Los Angeles, California • Mission Viejo, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Examining the Effects of a Mobilization With Movement and a Dynamic Stretch With Over Pressure on Hip Flexion.

NCT04762212
View directory record Official record
Conditions
Hip; Anomaly
Interventions
Mobilization with movement and stretching, stretching or control
Procedure
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Study of Oral Fampridine-SR in Multiple Sclerosis

NCT00127530
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional

Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00823732
View directory record Official record
Conditions
Lung Cancer
Interventions
educational intervention, medical chart review, questionnaire administration, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment, management of therapy complications, assessment of therapy complications
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Intervention to Improve Motor Skills in Young Children

NCT03901300
View directory record Official record
Conditions
Physical Activity, Fundamental Motor Skills, Development, Child, Self-regulation
Interventions
Fundamental Motor Skills App, Unstructured Physical Activity App
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
3 Years to 5 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 23, 2026, 5:51 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095
View directory record Official record
Conditions
Fistulizing Crohns Disease, Perianal Crohns Disease
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen-Cilag Ltd.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 23, 2026, 5:51 AM EDT
Completed No phase listed Observational

Collection of Liver Tissue for Virologic Studies

NCT00005936
View directory record Official record
Conditions
Virus Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Local Anesthesia and Pain Perception During an Amniocentesis

NCT00583011
View directory record Official record
Conditions
Pregnancy
Interventions
Local Anesthesia, Placebo Group
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

NCT00968812
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Canagliflozin (JNJ-28431754), Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
43
States / cities
Calera, Alabama • Gilbert, Arizona • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 23, 2026, 5:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impulsivity in Pathological Gambling

NCT00580567
View directory record Official record
Conditions
Pathological Gambling
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 23, 2026, 5:51 AM EDT
Terminated Phase 3 Interventional

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

NCT04684511
View directory record Official record
Conditions
Hemophilic Arthropathy
Interventions
TRM-201 (Rofecoxib), Placebo
Drug
Lead sponsor
Tremeau Pharmceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO

NCT02819011
View directory record Official record
Conditions
Accidental Falls, Fall Due to Loss of Equilibrium, High Risk of Falls Due to Mobility Limitation, Diabetes, Arthritis, Cancer, Peripheral Arterial Disease, Parkinson's Disease, End Stage Renal Failure on Dialysis
Interventions
MBB AFO, Control
Device · Other
Lead sponsor
Bijan Najafi, PhD
Other
Eligibility
65 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

NCT00490971
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine, Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
16
States / cities
Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

Liposomal Bupivacaine for Pain Control After Total Shoulder Arthroplasty

NCT02762071
View directory record Official record
Conditions
Osteoarthritis, Arthropathy, Shoulder Pain, Closed Fracture Proximal Humerus, Four Part
Interventions
Liposomal bupivacaine, Interscalene Nerve Block
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
20 Years to 100 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Columbia, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

NCT01366365
View directory record Official record
Conditions
Healthy Adults
Interventions
methylnaltrexone, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

NCT00107809
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 16 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
60
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

NCT03664739
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-120 Gel, IDp-120 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
25
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 23, 2026, 5:51 AM EDT